Table 3.
Univariate and Multivariate Cox Regression Analysis of Overall Survival for HNRNPM (n = 240)
| Characteristics | Univariate analysis |
Multivariate analysis |
||
|---|---|---|---|---|
| HR (95% CI) | P | HR (95% CI) | P | |
| Sex | ||||
| Female | 1.0 | |||
| Male | 1.0 (0.5–2.0) | .999 | ||
| Age | 1.0 (1.0–1.0) | .659 | ||
| HBsAg | ||||
| Negative | 1.0 | |||
| Positive | 0.9 (0.4–1.7) | .645 | ||
| Anti-HCV | ||||
| No | 1.0 | |||
| Yes | 1.8 (0.4–7.5) | .398 | ||
| Postoperative TACE | ||||
| No | 1.0 | |||
| Yes | 2.6 (1.7–4.1) | < .001 | ||
| Preoperative antivirus | ||||
| No | 1.0 | |||
| Yes | 0.8 (0.3–1.9) | .566 | ||
| Ascites | ||||
| No | 1.0 | |||
| Yes | 1.2 (0.5–2.9) | .742 | ||
| Macrovascular invasion | ||||
| No | 1.0 | |||
| Yes | 3.3 (1.8–6.2) | < .001 | ||
| Microvascular invasion | ||||
| No | 1.0 | 1.0 | ||
| Yes | 2.7 (0.8–8.7) | .099 | 2.2 (1.2–4.1) | .009 |
| Lymph node involved | ||||
| No | 1.0 | |||
| Yes | 0.7 (0.1–4.9) | .698 | ||
| Tumor number | ||||
| Single | 1.0 | |||
| Multiple | 1.0 (0.5–1.8) | .976 | ||
| Tumor grade | ||||
| I/II | 1.0 | 1.0 | ||
| III/IV | 1.8 (1.2–2.8) | .009 | 1.5 (1.0–2.3) | .031 |
| Preoperative AFP, ng/mL | ||||
| <400 | 1.0 | 1.0 | ||
| ≥400 | 1.3 (0.8–2.2) | .270 | 1.7 (1.1–2.7) | .014 |
| Tumor diameter, cm | ||||
| <5 | 1.0 | 1.0 | ||
| ≥5 | 2.5 (1.6–3.9) | < .001 | 2.1 (1.4–3.2) | < .001 |
| Preoperative AST, U/L | ||||
| <45 | 1.0 | 1.0 | ||
| ≥45 | 2.5 (1.5–4.0) | < .001 | 2.1 (1.4–3.4) | < .001 |
| Preoperative ALT, U/L | ||||
| <45 | 1.0 | |||
| ≥45 | 1.2 (0.7–2.0) | .426 | ||
| Preoperative bilirubin, um/L | ||||
| <28 | 1.0 | 1.0 | ||
| ≥28 | 14.8 (5.0–43.4) | < .001 | 10.4 (3.6–29.9) | < .001 |
| HNRNPM | ||||
| Low expression | 1.0 | 1.0 | ||
| High expression | 2.1 (1.3–3.8) | < .001 | 2.4 (1.6–3.6) | < .001 |
Note: Boldface P values indicate statistical significance.
AFP, α-fetoprotein; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; HBsAg, surface antigen of the hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; HNRNPM, heterogeneous nuclear ribonucleoprotein M; HR, hazard ratio; TACE, transhepatic arterial chemotherapy and embolization.